Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eurofarma's pegfilgrastim|DRUG: Neulastim
Sponsor: Eurofarma Laboratorios S.A.